Elanco Animal Health (ELAN) Asset Writedowns and Impairment (2017 - 2025)
Elanco Animal Health (ELAN) reported Asset Writedowns and Impairment of $47.0 million for Q4 2025, up 840.0% on a YoY basis from $5.0 million in Q4 2024, and up 95.83% sequentially from $24.0 million in Q3 2025.
Elanco Animal Health (ELAN) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Elanco Animal Health (ELAN) has 9 years of Asset Writedowns and Impairment data on file, last reported at $47.0 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 840.0% year-over-year to $47.0 million; the trailing twelve-month figure through Dec 2025 stood at $91.0 million (up 75.0% YoY), and the FY2025 full-year result was $71.0 million, down 12.35% from the prior year.
- Asset Writedowns and Impairment grew to $47.0 million in Q4 2025, from $24.0 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $275.0 million in Q2 2021 to a low of $5.0 million in Q4 2021.
- A 5-year average of $45.8 million and a median of $23.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment surged 9066.67% in 2021 and plunged 81.48% in 2024, its largest moves.
- Tracing ELAN's Asset Writedowns and Impairment over 5 years: stood at $5.0 million in 2021, then surged by 1080.0% to $59.0 million in 2022, then tumbled by 54.24% to $27.0 million in 2023, then plunged by 81.48% to $5.0 million in 2024, then soared by 840.0% to $47.0 million in 2025.
- Business Quant data shows ELAN's Asset Writedowns and Impairment at $47.0 million in Q4 2025, $24.0 million in Q3 2025, and $5.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Dec 31, 2023 | 27.00 Mn |
| Dec 31, 2023 | 27.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2022 | 59.00 Mn |
| Jun 30, 2022 | 59.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 56.00 Mn |
| Sep 30, 2021 | 56.00 Mn |